19 september 2011: Bron: Cancer. 2011 Aug 15;117(16):3774-80. doi: 10.1002/cncr.25933. Epub 2011 Feb 15.

Wanneer patienten met niet-klein-cellige longkanker naast chemo (Carboplatin, vinorelbine en Gemzar) aanvullend visolie krijgen dan blijkt de kans op aanslaan van de behandeling behoorlijk toe te nemen van 25% naar 60% (60.0% vs 25.8%, P = .008) en blijkt ook de effectiviteit van de behandeling significant toe te nemen, 80.0% vs 41.9%, P = .02. Nu is algemeen bekend dat chemo bij longkanker weinig doet maar uit deze studie blijkt dus dat visolie de potentie van chemo kan verbeteren. Dit blijkt uit een kleinschalige maar wel gerandomiseerde studie bij totaal 64 patienten met niet-klein-celiige longkanker. Hier het abstract van de studie. Het volledige studierapport kunt u tegen betaling inzien als u hier klikt.

Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.

Cancer. 2011 Aug 15;117(16):3774-80. doi: 10.1002/cncr.25933. Epub 2011 Feb 15.

Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.

Source

Division of Human Nutrition, Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.

Abstract

BACKGROUND:

Palliative chemotherapy is aimed at increasing survival and palliating symptoms. However, the response rate to first-line chemotherapy in patients with nonsmall cell lung cancer (NSCLC) is less than 30%. Experimental studies have shown that supplementation with fish oil (FO) can increase chemotherapy efficacy without negatively affecting nontarget tissue. This study evaluated whether the combination of FO and chemotherapy (carboplatin with vinorelbine or gemcitabine) provided a benefit over standard of care (SOC) on response rate and clinical benefit from chemotherapy in patients with advanced NSCLC.

METHODS:

Forty-six patients completed the study, n = 31 in the SOC group and n = 15 in the FO group (2.5 g EPA + DHA/day). Response to chemotherapy was determined by clinical examination and imaging. Response rate was defined as the sum of complete response plus partial response, and clinical benefit was defined as the sum of complete response, partial response, and stable disease divided by the number of patients. Toxicities were graded by a nurse before each chemotherapy cycle. Survival was calculated 1 year after study enrollment.

RESULTS:

Patients in the FO group had an increased response rate and greater clinical benefit compared with the SOC group (60.0% vs 25.8%, P = .008; 80.0% vs 41.9%, P = .02, respectively). The incidence of dose-limiting toxicity did not differ between groups (P = .46). One-year survival tended to be greater in the FO group (60.0% vs 38.7%; P = .15).

CONCLUSIONS:

Compared with SOC, supplementation with FO results in increased chemotherapy efficacy without affecting the toxicity profile and may contribute to increased survival.

Copyright © 2011 American Cancer Society.

PMID:
21328326
[PubMed - in process]

Plaats een reactie ...

Reageer op "Visolie verbetert significant responskans van chemo en visolie geeft naast chemo significant mediaan langere overleving bij niet-klein-cellige longkanker"


Gerelateerde artikelen
 

Gerelateerde artikelen

All-Trans-Retinoic Acid - >> Antioxidanten - vitamines >> Acetylcysteine (Glutathion) >> Astragalus polysaccharide >> Bexarotene - een bewerkte >> Broccoli voorkomt longkanker >> Chinese kruiden mix - injecties >> Hydrazine sulfaat vermindert >> Melatonine naast chemo geeft >> OK-432 zorgt in vergelijking >>